Pentosan Polysulfate Tracker App

Pentosan Polysulfate for osteoarthritis is used off-label via subcutaneous injection — the route that achieves therapeutic synovial fluid concentrations that oral dosing does not reliably provide. Doses used in clinical OA studies and off-label practice: 2 mg/kg SC once weekly — the dose used in the landmark PENS-OA trial (Ghosh et al., 2020) which demonstrated significant improvements in WOMAC pain and function scores versus placebo. 1.5 mg/kg SC twice weekly — an alternative protocol used in some practice settings for more continuous synovial exposure. Treatment course: 4–6 weeks of weekly injections is considered the minimum effective treatment; 8–12 weeks produces more durable benefits. Repeat courses: 1–2 courses per year are typical for maintenance. For a 75 kg individual, 2 mg/kg = 150 mg SC per injection. PPS is available as a sterile 100 mg/mL injectable solution; smaller volumes (0.15–0.3 mL) are injected subcutaneously in the abdomen or thigh. When tracking in Shotlee, log the exact dose in mg (calculated from body weight), injection site, and any local reactions. Pain score improvements typically begin 4–6 weeks into the treatment course — continue logging weekly to capture the full response trajectory.

Pentosan Polysulfate Sodium is used in two entirely different forms and indications. Elmiron (oral PPS): FDA-approved at 100 mg three times daily (300 mg/day total) for interstitial cystitis/bladder pain syndrome (IC/BPS). Oral PPS works for IC because it directly contacts the bladder urothelium via urinary excretion — the drug is excreted through urine and provides a direct protective coating effect on the bladder wall, replacing the deficient glycosaminoglycan layer that leads to IC symptoms. Oral bioavailability is only 3–6%, but this is sufficient for the bladder urothelial surface contact mechanism. Injectable PPS (off-label, OA): subcutaneous injection achieves 10–20x higher systemic concentrations than oral dosing, sufficient to reach therapeutic levels in synovial fluid and articular cartilage. This is why injection is necessary for osteoarthritis — oral doses do not produce adequate concentrations in joint tissue. Side effect difference: Elmiron (oral) is associated with a rare but serious retinal pigment epithelopathy (maculopathy) with prolonged use — patients on Elmiron long-term need annual eye exams. Injectable PPS does not appear to carry the same ophthalmological risk at the lower doses and durations used for OA. Track your PPS form, dose, and indication clearly in Shotlee to distinguish IC oral therapy from OA injection protocols.

Open the Shotlee app, navigate to the dose logging screen, select Pentosan as your medication, and enter the dose amount, injection site, and time. Shotlee stores all entries with timestamps and lets you view your complete dose history, adherence rate, and missed dose alerts. The app is free to download and use.

The most important side effects to track include gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), injection site reactions, appetite changes, energy levels, and any unusual symptoms. Log these daily in Shotlee so you can share accurate trend data with your healthcare provider at your next visit.

Most patients begin noticing appetite changes within the first one to two weeks. Measurable weight loss typically becomes apparent by weeks four to eight, depending on the dose titration schedule and individual metabolic response. Track your weekly weight in Shotlee to visualize your personal response curve over time.

Download Shotlee for free from the App Store, create your profile, and navigate to the dose logging screen. Select Pentosan as your medication, then begin logging each dose with the exact amount, time, and injection site. Shotlee will automatically generate trend charts and adherence reports from your entries, giving you and your healthcare provider clear visibility into your protocol progress.

The highest-value metrics to track are: dose amount and timing for adherence monitoring, daily side effect type and severity for tolerability assessment, weekly fasting body weight under consistent conditions for efficacy tracking, waist circumference and body measurements for composition changes, lab results including metabolic panels and lipid profiles for safety monitoring, and daily appetite and energy ratings for subjective response assessment. Shotlee supports all of these in a single integrated dashboard.

Yes. Shotlee generates comprehensive reports from your tracking data that you can share with your healthcare provider during appointments. Having objective longitudinal data — rather than relying on memory — enables more efficient clinical consultations, more personalized dose adjustments, and better overall treatment outcomes. Many users find that sharing their Shotlee data significantly improves the quality of their provider interactions.